The new company was structured as a Sino-Foreign Equity Joint Venture and seeks to develop and commercialize a variety of products including pharmaceutical, functional foods, and nutraceuticals for China and the world. However SemBioSys did not transfer any intellectual property to the joint venture and Tasly terminated the agreement.
The new company was established as a Sino-foreign partnership, with objectives encompassing product development and global distribution of pharmaceuticals, functional foods, and nutraceuticals. However, SemBioSys did not transfer any intellectual property to the joint venture, and Tasly ultimately ended the collaboration.